1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow CytoAgents, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy CTO1681 10 µg, CTO1681 20 μg, CTO1681 30 μg - Cytokine Release Syndrome | Phase 1 / Phase 2 | Recruiting | CytoAgents, Inc. | 54 | 2023-12-28 | 2026-08-31 |
Therapeutics (1)
United States (1)
Mike Howell, PhD (1)
R44CA295189 (1)